
Between January 2001 and January 2012, 48 new medicinal products for cancer treatment were licensed within the zzso and 77 new indications were granted for products already zzso In some cases, a major improvement to existing therapies was zzso for example, zzso in breast zzso In other cases, new fields for effective drug therapy opened up, such as in chronic zzso zzso and zzso zzso In most cases, however, the zzso balance was considered to be only borderline zzso Based on our assessment of advice procedures for marketing authorization, zzso for zzso seems to be the guiding principle in zzso drug zzso zzso for drugs that make a difference, early zzso is of obvious importance to patients, this is less evident in the case of borderline zzso Without proper incentives and with hurdles inside and outside companies, a change in drug development cannot be zzso drugs improving zzso modestly over available therapies will be brought forward towards zzso In this Perspectives article, we discuss some hurdles to zzso drug development and provide some suggestions to overcome zzso 

